vs
和黄医药（HCM）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
和黄医药的季度营收约是BRC Group Holdings, Inc.的1.4倍（$270.8M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 0.7%，领先47.2%），和黄医药同比增速更快（-16.5% vs -21.9%）
和黄医药是一家国际化生物制药企业，专注于肿瘤、免疫类疾病的靶向疗法与免疫疗法的研发、生产及商业化，核心市场覆盖中国及全球多个国家地区，已有多款肿瘤治疗药物上市，后期临床管线储备丰富。
HCM vs RILY — 直观对比
营收规模更大
HCM
是对方的1.4倍
$188.3M
营收增速更快
HCM
高出5.3%
-21.9%
净利率更高
RILY
高出47.2%
0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $270.8M | $188.3M |
| 净利润 | $2.0M | $90.3M |
| 毛利率 | 37.7% | 79.5% |
| 营业利润率 | -13.2% | 32.3% |
| 净利率 | 0.7% | 47.9% |
| 营收同比 | -16.5% | -21.9% |
| 净利润同比 | -83.6% | 1710.8% |
| 每股收益（稀释后） | $0.00 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCMRILY
| Q4 25 | $270.8M | $188.3M | ||
| Q3 25 | — | $215.3M | ||
| Q2 25 | $277.7M | $188.2M | ||
| Q1 25 | $324.5M | $197.2M | ||
| Q4 24 | — | $241.0M | ||
| Q3 24 | — | $225.5M | ||
| Q2 24 | $305.7M | $256.0M | ||
| Q1 24 | — | $263.4M |
净利润HCMRILY
| Q4 25 | $2.0M | $90.3M | ||
| Q3 25 | — | $91.1M | ||
| Q2 25 | $455.0M | $139.5M | ||
| Q1 25 | $11.9M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $-284.4M | ||
| Q2 24 | $25.8M | $-433.6M | ||
| Q1 24 | — | $-49.2M |
毛利率HCMRILY
| Q4 25 | 37.7% | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | 0.1% | 81.3% | ||
| Q1 25 | 48.0% | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | 41.1% | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率HCMRILY
| Q4 25 | -13.2% | 32.3% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | -1.3% | 5.7% | ||
| Q1 25 | -5.0% | -31.2% | ||
| Q4 24 | — | -69.2% | ||
| Q3 24 | — | -36.4% | ||
| Q2 24 | -9.0% | -90.8% | ||
| Q1 24 | — | -6.1% |
净利率HCMRILY
| Q4 25 | 0.7% | 47.9% | ||
| Q3 25 | — | 42.3% | ||
| Q2 25 | 163.8% | 74.1% | ||
| Q1 25 | 3.7% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -126.1% | ||
| Q2 24 | 8.4% | -169.4% | ||
| Q1 24 | — | -18.7% |
每股收益（稀释后）HCMRILY
| Q4 25 | $0.00 | $2.78 | ||
| Q3 25 | — | $2.91 | ||
| Q2 25 | $0.52 | $4.50 | ||
| Q1 25 | $0.01 | $-0.39 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | $0.03 | $-14.35 | ||
| Q1 24 | — | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $226.6M |
| 总债务越低越好 | $93.2M | $1.4B |
| 股东权益账面价值 | $1.2B | $-171.5M |
| 总资产 | $1.8B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.08× | — |
8季度趋势，按日历期对齐
现金及短期投资HCMRILY
| Q4 25 | $1.4B | $226.6M | ||
| Q3 25 | — | $184.2M | ||
| Q2 25 | $1.4B | $267.4M | ||
| Q1 25 | $836.1M | $138.3M | ||
| Q4 24 | — | $146.9M | ||
| Q3 24 | — | $159.2M | ||
| Q2 24 | $802.5M | $236.9M | ||
| Q1 24 | — | $190.7M |
总债务HCMRILY
| Q4 25 | $93.2M | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $93.4M | $1.3B | ||
| Q1 25 | $82.8M | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | $82.1M | — | ||
| Q1 24 | — | — |
股东权益HCMRILY
| Q4 25 | $1.2B | $-171.5M | ||
| Q3 25 | — | $-260.5M | ||
| Q2 25 | $1.2B | $-351.7M | ||
| Q1 25 | $759.9M | $-496.8M | ||
| Q4 24 | — | $-488.2M | ||
| Q3 24 | — | $-497.6M | ||
| Q2 24 | $740.1M | $-218.3M | ||
| Q1 24 | — | $228.4M |
总资产HCMRILY
| Q4 25 | $1.8B | $1.7B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | $1.8B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | $1.3B | $3.2B | ||
| Q1 24 | — | $5.0B |
负债/权益比HCMRILY
| Q4 25 | 0.08× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.2M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $3.4M | — |
| 自由现金流率自由现金流/营收 | 1.2% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | 4.21× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $-96.2M | — |
8季度趋势，按日历期对齐
经营现金流HCMRILY
| Q4 25 | $8.2M | $26.2M | ||
| Q3 25 | — | $-60.6M | ||
| Q2 25 | $-72.9M | $-25.6M | ||
| Q1 25 | $40.3M | $184.0K | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | $-39.8M | $111.5M | ||
| Q1 24 | — | $135.4M |
自由现金流HCMRILY
| Q4 25 | $3.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-82.2M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-49.9M | — | ||
| Q1 24 | — | — |
自由现金流率HCMRILY
| Q4 25 | 1.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -29.6% | — | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -16.3% | — | ||
| Q1 24 | — | — |
资本支出强度HCMRILY
| Q4 25 | 1.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | — | — |
现金转化率HCMRILY
| Q4 25 | 4.21× | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | -0.16× | -0.18× | ||
| Q1 25 | 3.38× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.54× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCM
暂无分部数据
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
